MassIVE MSV000091570

Partial Public

IDR-Targeting Compounds Suppress HPV Genome Replication via Disruption of Phospho-BRD4 Association with DNA Damage Response Factors

Description

Sample name abbreviation is below. Cell State: Prol for proliferation, Diff for differentiation Compound (cpd) treatment: DMSO for DMSO-only treatment, 14 or 90 for compound pNPS14 or pNPS90 treatment BRD4-L IP: L1, L2, and L3 for anti-BRD4-L IP samples 1, 2, and 3 BRD4-S IP: S1, S2, and S3 for anti-BRD4-S IP samples 1, 2, and 3 IgG IP: Ig1, Ig2, and Ig3 for IgG IP samples 1, 2, and 3 Sample ID vs. sample name is listed below. 967246 / Prol_DMSO_L1, 967247 / Prol_DMSO_L2, 967248 / Prol_DMSO_L3 967249 / Prol_14_L1, 967250 / Prol_14_L2, 967251 / Prol_14_L3 967252 / Prol_10_L1, 967253 / Prol_10_L2, 967254 / Prol_10_L3 967255 / Prol_DMSO_S1, 967256 / Prol_DMSO_S2, 967257 / Prol_DMSO_S3 967258 / Prol_14_S1, 967259 / Prol_14_S2, 967260 / Prol_14_S3 967261 / Prol_10_S1, 967262 / Prol_10_S2, 967263 / Prol_10_S3 967264 / Diff_DMSO_L1, 967265 / Diff_DMSO_L2, 967266 / Diff_DMSO_L3 967267 / Diff_14_L1, 967268 / Diff_14_L2, 967269 / Diff_14_L3 967270 / Diff_10_L1, 967271 / Diff_10_L2, 967272 / Diff_10_L3 967273 / Diff_DMSO_S1, 967274 / Diff_DMSO_S2, 967275 / Diff_DMSO_S3 967276 / Diff_14_S1, 967277 / Diff_14_S2, 967278 / Diff_14_S3 967279 / Diff_10_S1, 967280 / Diff_10_S2, 967281 / Diff_10_S3 967282 / Prol_DMSO_Ig1, 967283 / Prol_DMSO_Ig2, 967284 / Prol_DMSO_Ig3 967285 / Diff_DMSO_Ig1, 967286 / Diff_DMSO_Ig2, 967287 / Diff_DMSO_Ig3 [doi:10.25345/C5JH3DC4M] [dataset license: CC0 1.0 Universal (CC0 1.0)]

Keywords: BRD4 ; BET ; HPV ; small compounds ; PPI inhibitors

Contact

Principal Investigators:
(in alphabetical order)
Cheng-Ming Chiang, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, USA
Submitting User: alemoff

Publications

Wu, S.-Y., Lai, H.T., Banerjee, N.S., Ma, Z., Santana, J.F., Wei, S., Liu, X., Zhang, M., Zhan, J., Chen, H., Posner, B., Chen, Y., Price, D.H., Chow, L.T., Zhou, J., & Chiang, C.-M.
IDR-targeting compounds suppress HPV genome replication via disruption of phospho-BRD4 association with DNA damage response factors.
https://doi.org/10.1016/j.molcel.2023.11.022.

Number of Files:
Total Size:
Spectra:
Subscribers:
 
Owner Reanalyses
Experimental Design
    Conditions:
    Biological Replicates:
    Technical Replicates:
 
Identification Results
    Proteins (Human, Remapped):
    Proteins (Reported):
    Peptides:
    Variant Peptides:
    PSMs:
 
Quantification Results
    Differential Proteins:
    Quantified Proteins:
 
Browse Dataset Files
 
FTP Download Link (click to copy):

- Dataset Reanalyses


+ Dataset History


Click here to queue conversion of this dataset's submitted spectrum files to open formats (e.g. mzML). This process may take some time.

When complete, the converted files will be available in the "ccms_peak" subdirectory of the dataset's FTP space (accessible via the "FTP Download" link to the right).
Number of distinct conditions across all analyses (original submission and reanalyses) associated with this dataset.

Distinct condition labels are counted across all files submitted in the "Metadata" category having a "Condition" column in this dataset.

"N/A" means no results of this type were submitted.
Number of distinct biological replicates across all analyses (original submission and reanalyses) associated with this dataset.

Distinct replicate labels are counted across all files submitted in the "Metadata" category having a "BioReplicate" or "Replicate" column in this dataset.

"N/A" means no results of this type were submitted.
Number of distinct technical replicates across all analyses (original submission and reanalyses) associated with this dataset.

The technical replicate count is defined as the maximum number of times any one distinct combination of condition and biological replicate was analyzed across all files submitted in the "Metadata" category. In the case of fractionated experiments, only the first fraction is considered.

"N/A" means no results of this type were submitted.
Originally identified proteins that were automatically remapped by MassIVE to proteins in the SwissProt human reference database.

"N/A" means no results of this type were submitted.
Number of distinct protein accessions reported across all analyses (original submission and reanalyses) associated with this dataset.

"N/A" means no results of this type were submitted.
Number of distinct unmodified peptide sequences reported across all analyses (original submission and reanalyses) associated with this dataset.

"N/A" means no results of this type were submitted.
Number of distinct peptide sequences (including modified variants or peptidoforms) reported across all analyses (original submission and reanalyses) associated with this dataset.

"N/A" means no results of this type were submitted.
Total number of peptide-spectrum matches (i.e. spectrum identifications) reported across all analyses (original submission and reanalyses) associated with this dataset.

"N/A" means no results of this type were submitted.
Number of distinct proteins quantified across all analyses (original submission and reanalyses) associated with this dataset.

Distinct protein accessions are counted across all files submitted in the "Statistical Analysis of Quantified Analytes" category having a "Protein" column in this dataset.

"N/A" means no results of this type were submitted.
Number of distinct proteins found to be differentially abundant in at least one comparison across all analyses (original submission and reanalyses) associated with this dataset.

A protein is differentially abundant if its change in abundance across conditions is found to be statistically significant with an adjusted p-value <= 0.05 and lists no issues associated with statistical tests for differential abundance.

Distinct protein accessions are counted across all files submitted in the "Statistical Analysis of Quantified Analytes" category having a "Protein" column in this dataset.

"N/A" means no results of this type were submitted.
This dataset may not contain all raw spectra data as originally deposited in PRIDE. It has been imported to MassIVE for reanalysis purposes, so its spectra data here may consist solely of processed peak lists suitable for reanalysis with most software.